MX2023009995A - Composiciones que incluyen adyuvantes de sbi y metodos para usarlos. - Google Patents
Composiciones que incluyen adyuvantes de sbi y metodos para usarlos.Info
- Publication number
- MX2023009995A MX2023009995A MX2023009995A MX2023009995A MX2023009995A MX 2023009995 A MX2023009995 A MX 2023009995A MX 2023009995 A MX2023009995 A MX 2023009995A MX 2023009995 A MX2023009995 A MX 2023009995A MX 2023009995 A MX2023009995 A MX 2023009995A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- adjuvants
- compositions including
- sbi
- fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156860P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/018610 WO2022187424A1 (en) | 2021-03-04 | 2022-03-03 | Compositions including sbi adjuvants and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009995A true MX2023009995A (es) | 2023-11-22 |
Family
ID=80820175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009995A MX2023009995A (es) | 2021-03-04 | 2022-03-03 | Composiciones que incluyen adyuvantes de sbi y metodos para usarlos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11771758B2 (enExample) |
| EP (1) | EP4301404A1 (enExample) |
| JP (2) | JP2024508683A (enExample) |
| KR (1) | KR20230154048A (enExample) |
| CN (2) | CN116916950A (enExample) |
| AU (2) | AU2022228575C1 (enExample) |
| BR (1) | BR112023017749A2 (enExample) |
| CA (1) | CA3211083A1 (enExample) |
| IL (2) | IL320523A (enExample) |
| MX (1) | MX2023009995A (enExample) |
| WO (1) | WO2022187424A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060631A1 (en) * | 2017-09-20 | 2019-03-28 | Helix Nanotechnologies, Inc. | EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE |
| WO2022187424A1 (en) | 2021-03-04 | 2022-09-09 | Helix Nanotechnologies, Inc. | Compositions including sbi adjuvants and methods of use thereof |
| WO2024152844A1 (zh) * | 2023-01-19 | 2024-07-25 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2奥密克戎突变株及其亚型感染的蛋白及疫苗 |
| US12559515B2 (en) | 2023-12-22 | 2026-02-24 | Helix Nanotechnologies Inc | Cap compounds and RNAS comprising the same |
| US20250270299A1 (en) * | 2024-01-31 | 2025-08-28 | Helix Nanotechnologies Inc | Methods of using compositions comprising sbi domains |
| WO2025166067A1 (en) | 2024-01-31 | 2025-08-07 | Helix Nanotechnologies, Inc. | Sars-cov-2 vaccine compositions and methods |
| WO2026015884A1 (en) | 2024-07-11 | 2026-01-15 | Helix Nanotechnologies Inc | Compositions comprising ire-1 binding sequences and uses thereof |
| WO2026084768A1 (en) | 2024-10-16 | 2026-04-23 | Helix Nanotechnologies Inc | Helper proteins for increased secretion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485904B1 (en) * | 1997-06-23 | 2002-11-26 | Pfizer, Inc. | DNA encoding a plasminogen activating protein |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2002072792A2 (en) * | 2001-03-13 | 2002-09-19 | Corixa Corporation | Heterologous fusion protein constructs comprising a leishmania antigen |
| GB0605735D0 (en) * | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| GB0610776D0 (en) | 2006-05-31 | 2006-07-12 | Univ Bath | Novel applications for staphylococcus aureus Sbi protein |
| GB201016403D0 (en) | 2010-09-29 | 2010-11-10 | Bath Ventures | Novel interaction between staphylococcus aureus Sbi and C3d protiens |
| SG11201602012RA (en) * | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
| GB201619965D0 (en) | 2016-11-25 | 2017-01-11 | Univ Of Bath The | Immunogenic compositions comprising sbi protein and uses thereof |
| CN110168090B (zh) * | 2016-12-27 | 2023-07-18 | 国立大学法人东京大学 | mRNA的功能化方法 |
| MA54192A (fr) * | 2018-11-07 | 2021-09-15 | Modernatx Inc | Vaccins à arn contre le cancer |
| US20220280633A1 (en) * | 2019-07-30 | 2022-09-08 | Verndari, Inc. | Virus-like particle vaccines |
| KR20230039607A (ko) * | 2020-05-06 | 2023-03-21 | 징코 바이오웍스, 인크. | 변이체 SARS-CoV-2 단백질 및 그의 용도 |
| WO2022187424A1 (en) | 2021-03-04 | 2022-09-09 | Helix Nanotechnologies, Inc. | Compositions including sbi adjuvants and methods of use thereof |
-
2022
- 2022-03-03 WO PCT/US2022/018610 patent/WO2022187424A1/en not_active Ceased
- 2022-03-03 MX MX2023009995A patent/MX2023009995A/es unknown
- 2022-03-03 JP JP2023547793A patent/JP2024508683A/ja not_active Withdrawn
- 2022-03-03 AU AU2022228575A patent/AU2022228575C1/en active Active
- 2022-03-03 EP EP22711777.7A patent/EP4301404A1/en active Pending
- 2022-03-03 KR KR1020237033198A patent/KR20230154048A/ko active Pending
- 2022-03-03 BR BR112023017749A patent/BR112023017749A2/pt unknown
- 2022-03-03 CN CN202280016257.9A patent/CN116916950A/zh active Pending
- 2022-03-03 CN CN202411062411.3A patent/CN119161490A/zh active Pending
- 2022-03-03 US US17/685,717 patent/US11771758B2/en active Active
- 2022-03-03 IL IL320523A patent/IL320523A/en unknown
- 2022-03-03 IL IL305333A patent/IL305333B2/en unknown
- 2022-03-03 CA CA3211083A patent/CA3211083A1/en active Pending
-
2023
- 2023-08-18 US US18/235,464 patent/US12343392B2/en active Active
-
2024
- 2024-12-06 JP JP2024213919A patent/JP2025026590A/ja active Pending
-
2025
- 2025-05-27 US US19/218,897 patent/US20260061048A1/en active Pending
- 2025-07-02 AU AU2025205053A patent/AU2025205053A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240082388A1 (en) | 2024-03-14 |
| CN116916950A (zh) | 2023-10-20 |
| WO2022187424A1 (en) | 2022-09-09 |
| CA3211083A1 (en) | 2022-09-09 |
| US20260061048A1 (en) | 2026-03-05 |
| CN119161490A (zh) | 2024-12-20 |
| US11771758B2 (en) | 2023-10-03 |
| US12343392B2 (en) | 2025-07-01 |
| AU2022228575B2 (en) | 2025-04-03 |
| AU2022228575A1 (en) | 2023-10-12 |
| IL305333B1 (en) | 2025-06-01 |
| NZ804057A (en) | 2025-07-25 |
| EP4301404A1 (en) | 2024-01-10 |
| JP2024508683A (ja) | 2024-02-28 |
| IL305333B2 (en) | 2025-10-01 |
| US20220362373A1 (en) | 2022-11-17 |
| IL320523A (en) | 2025-06-01 |
| KR20230154048A (ko) | 2023-11-07 |
| AU2022228575C1 (en) | 2025-10-09 |
| BR112023017749A2 (pt) | 2023-10-03 |
| JP2025026590A (ja) | 2025-02-21 |
| AU2025205053A1 (en) | 2025-07-24 |
| IL305333A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013859A (es) | Polipeptidos modificados. | |
| MX2021003580A (es) | Nuevas inmunocitocinas para el tratamiento contra el cancer. | |
| WO2007106476A3 (en) | Compositions and methods for enhancing the immunogenicity of antigens | |
| BR112023017749A2 (pt) | Composições incluindo adjuvantes sbi e métodos de uso das mesmas | |
| MX2022011411A (es) | Proteinas de union a antigeno que se unen especificamente a mage-a. | |
| PH12021500051A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| PH12022550195A1 (en) | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| MX2024003807A (es) | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos. | |
| MX2023001595A (es) | Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas. | |
| NZ606427A (en) | Extended recombinant polypeptides and compositions comprising same | |
| WO2006036550A3 (en) | Listeria-based and llo-based vaccines | |
| MX2024007393A (es) | Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos. | |
| EA199800973A1 (ru) | Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение | |
| UA87106C2 (uk) | БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ РЕЦЕПТОР Nogo | |
| AU2003239659A1 (en) | Peptide epitopes common to antigens of the same multigene family | |
| ZA202402034B (en) | Caix targeting il-12 fusion proteins and methods of use thereof | |
| MX2025013732A (es) | Anticuerpos de dominio unico modificados | |
| SA520420336B1 (ar) | C أجسام مضادة مُطعمة بببتيد مدر للصوديوم من النوع | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| MX2024015643A (es) | Polipéptidos de unión al antígeno contra el coronavirus 2 del síndrome respiratorio agudo grave (anti-sars-cov-2), complejos de polipéptidos y métodos de uso de estos | |
| WO2021239838A3 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
| WO2021252974A3 (en) | Collagen-targeted fusion proteins and antibodies | |
| WO2019210055A3 (en) | Heat shock protein-binding peptide compositions and methods of use thereof | |
| MX2009003679A (es) | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. |